Lupus

Frequent mental distress is commonly reported among adults with arthritis across all 50 states and Washington, D.C., with the highest prevalence reported in the Appalachian region and southern states, according to data published in Morbidity and Mortality Weekly Report.

Patients with systemic lupus erythematosus had a higher rate of British Isles Lupus Assessment Group-based Composite Lupus Assessment, or BICLA, response with anifrolumab compared with placebo, according to data from the TULIP-2 study, published in The New England Journal of Medicine.

Glucocorticoid treatments contribute to organ damage accrual in patients with systemic lupus erythematosus, independent of clinical or serological disease activity, according to data published in The Lancet Rheumatology.

As 2019 draws to a close, Healio reflects on the top news in dermatology from not only the past year, but the past 10 years, as we welcome a new decade of discoveries and practice-changing approvals.

Ustekinumab provides sustained clinical benefits through 1 year among patients with systemic lupus erythematosus, with a safety profile similar with its other indications, according to data published in Arthritis & Rheumatology.

Patients newly diagnosed with systemic lupus erythematosus demonstrate a 62% increased risk for hip fractures compared with those without lupus, according to data published in Arthritis Care & Research.

Intense dust cloud inhalation, as well as PTSD, experienced by first responders and community members present at the Sept. 11 terrorist attack in New York are associated with a significant increased risk for systemic autoimmune disease, including rheumatoid arthritis and lupus, according to findings published in Arthritis & Rheumatology.

New treatments and trial designs, particularly focused on patients with refractory disease, remain among the top unmet needs in rheumatology in 2019, according to expert opinions culled from the Advances in Target Therapies annual meeting and published in the Annals of the Rheumatic Diseases.

Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.

Hair loss in systemic lupus erythematosus can indicate active disease, and nonscarring alopecia shows changes unique to lupus on histology and direct immunofluorescence, according to researchers in Journal of the American Academy of Dermatology.